Sanofi (France)
NEWS
Public health officials begin to think we’ve turned the corner on the pandemic as new global cases drop 21% last week, the third consecutive week numbers and deaths have declined.
After roaring into February with positive data in five different indications, Regeneron and Sanofi announced today a late-stage Dupixent trial has been halted due to futility.
Star Therapeutics has exited stealth mode and announced a spin-off company, Electra Therapeutics.
For 2021, with $6.19 billion in sales the monoclonal antibody counted for a little less than one-third of Regeneron’s overall $16.07 billion revenue.
After 50 years, Sanofi is giving itself a bit of a branding make-over with a new logo and a restructuring of its corporate umbrella supporting its three-year-old “Play to Win” strategy.
The FDA had accepted the sBLA in September 2021 under priority review status.
The companies announced that Dupixent was the first biologic to significantly reduce itch and skin lesions in patients with Prurigo Nodularis in the Phase III trial.
Sanofi has signed a collaboration deal with Exscientia to leverage the latter’s artificial intelligence platform and develop up to 15 oncology and immunology therapies.
Under the terms of the deal, Sanofi is paying Amunix $1 billion up front and up to $225 million in various development milestone payments.
JOBS
IN THE PRESS